189 related articles for article (PubMed ID: 24212616)
1. Targeting apoptosis signaling in pancreatic cancer.
Fulda S
Cancers (Basel); 2011 Jan; 3(1):241-51. PubMed ID: 24212616
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis pathways and their therapeutic exploitation in pancreatic cancer.
Fulda S
J Cell Mol Med; 2009 Jul; 13(7):1221-7. PubMed ID: 19382915
[TBL] [Abstract][Full Text] [Related]
3. Targeting apoptotic signaling pathways in human lung cancer.
Han SW; Roman J
Curr Cancer Drug Targets; 2010 Sep; 10(6):566-74. PubMed ID: 20482489
[TBL] [Abstract][Full Text] [Related]
4. Cell death in hematological tumors.
Fulda S
Apoptosis; 2009 Apr; 14(4):409-23. PubMed ID: 19130230
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor of apoptosis proteins as targets for anticancer therapy.
Fulda S
Expert Rev Anticancer Ther; 2007 Sep; 7(9):1255-64. PubMed ID: 17892425
[TBL] [Abstract][Full Text] [Related]
6. Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis.
Lebedeva IV; Su ZZ; Sarkar D; Gopalkrishnan RV; Waxman S; Yacoub A; Dent P; Fisher PB
Oncogene; 2005 Jan; 24(4):585-96. PubMed ID: 15580305
[TBL] [Abstract][Full Text] [Related]
7. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.
Yuan K; Sun Y; Zhou T; McDonald J; Chen Y
Clin Cancer Res; 2013 Sep; 19(17):4750-9. PubMed ID: 23833311
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia.
Fulda S
Br J Haematol; 2009 May; 145(4):441-54. PubMed ID: 19298593
[TBL] [Abstract][Full Text] [Related]
9. Exploiting death receptor signaling pathways for tumor therapy.
Fulda S; Debatin KM
Biochim Biophys Acta; 2004 Dec; 1705(1):27-41. PubMed ID: 15585171
[TBL] [Abstract][Full Text] [Related]
10. Targeting nonapoptotic pathways with functionalized nanoparticles for cancer therapy: current and future perspectives.
Yadav M; Niveria K; Sen T; Roy I; Verma AK
Nanomedicine (Lond); 2021 May; 16(12):1049-1065. PubMed ID: 33970686
[TBL] [Abstract][Full Text] [Related]
11. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells.
Su Z; Lebedeva IV; Gopalkrishnan RV; Goldstein NI; Stein CA; Reed JC; Dent P; Fisher PB
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10332-7. PubMed ID: 11526239
[TBL] [Abstract][Full Text] [Related]
12. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
13. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
14. Lentivirus-mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti-tumor effect of dendritic cell vaccination against pancreatic cancer in SCID-hu mice.
Wang J; Sun M; Zhu X; Zhao H; Mao D; Zhang Z; Zhao X
Oncol Lett; 2019 Aug; 18(2):1539-1547. PubMed ID: 31423221
[TBL] [Abstract][Full Text] [Related]
15. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
16. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract][Full Text] [Related]
17. The mechanism of necroptosis in normal and cancer cells.
Fulda S
Cancer Biol Ther; 2013 Nov; 14(11):999-1004. PubMed ID: 24025353
[TBL] [Abstract][Full Text] [Related]
18. Targeting apoptosis resistance in rhabdomyosarcoma.
Fulda S
Curr Cancer Drug Targets; 2008 Sep; 8(6):536-44. PubMed ID: 18781899
[TBL] [Abstract][Full Text] [Related]
19. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
Chen H; Li L; Hu J; Zhao Z; Ji L; Cheng C; Zhang G; Zhang T; Li Y; Chen H; Pan S; Sun B
J Exp Clin Cancer Res; 2019 Jul; 38(1):297. PubMed ID: 31288830
[TBL] [Abstract][Full Text] [Related]
20. PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells.
Ozpolat B; Akar U; Mehta K; Lopez-Berestein G
Autophagy; 2007; 3(5):480-3. PubMed ID: 17507797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
